Mosby's Drug Guide for Nursing Students, 10th Edition
Description:
No nursing student should leave home without this book! Mosby's Drug Guide for Nursing Students, 10th Edition offers the most reliable information, now presented in full color. With an A to Z organization, you have quick access to information on 50 drug classifications and more than 4,000 individual generic and trade name drugs. The newest NANDA-I nursing diagnoses help you write care plans, and data on interactions and therapeutic outcomes help you prevent errors. Detailed illustrations show how drugs work at the cellular level, and a photo atlas depicts physical landmarks and techniques for safe and effective drug administration. Known for its focus on drug safety, this handbook is compiled by Linda Skidmore-Roth, a well-known expert in nursing pharmacology, which means you will ALWAYS find the latest and most trustworthy drug information. An Evolve companion website includes profiles of several drugs commonly encountered in clinicals, vibrant animations of drug actions, comprehensive list of combination products, patient-teaching guides, clinical calculators, and more!
2014 Update includes 23 recently approved drugs.
Best prices to buy, sell, or rent ISBN 9780323172967
Frequently Asked Questions about Mosby's Drug Guide for Nursing Students, 10th Edition
The price for the book starts from $7.92 on Amazon and is available from 11 sellers at the moment.
If you’re interested in selling back the Mosby's Drug Guide for Nursing Students, 10th Edition book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Mosby's Drug Guide for Nursing Students, 10th Edition book, the best buyback offer comes from and is $ for the book in good condition.
The Mosby's Drug Guide for Nursing Students, 10th Edition book is in very low demand now as the rank for the book is 4,844,960 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.